瑞丹韋單抗
瑞丹韋單抗（INN：Regdanvimab），以商品名Regkirona出售，是一種用於治療COVID-19的人單克隆抗體。[4]該抗體針對SARS-CoV-2的刺突蛋白。它是由賽特瑞恩（Celltrion）開發的。[6][7]該藥物通過靜脈輸注（滴注）給藥。[4][8]
| 單克隆抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | SARS-CoV-2的刺突蛋白 |
| 臨床資料 | |
| 商品名 | Regkirona |
| 其他名稱 | 瑞達韋單抗、瑞丹維單抗、CT-P59 |
| 核准狀況 | |
| 懷孕分級 | |
| 給藥途徑 | 靜脈注射 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 | |
| 識別資訊 | |
| CAS號 | 2444308-95-4 |
| DrugBank | |
| UNII | |
| KEGG | |
參考資料
編輯- ^ Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 12 May 2022 [13 May 2022]. （原始內容存檔於3 April 2022）.
- ^ AusPAR: Regdanvimab. Therapeutic Goods Administration (TGA). 7 December 2021 [4 January 2022]. （原始內容存檔於5 January 2022）.
- ^ TGA Provisional Approval of Celltrion Healthcare Australia Pty Ltd COVID-19 treatment, regdanvimab (Regkirona). Therapeutic Goods Administration (TGA) (新聞稿). 6 December 2021 [4 January 2022]. （原始內容存檔於5 January 2022）.
- ^ 4.0 4.1 4.2 4.3 4.4 Regkirona EPAR. European Medicines Agency. 10 November 2021 [12 November 2021]. （原始內容存檔於12 November 2021）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 5.0 5.1 Regkirona. Union Register of medicinal products. 12 November 2021 [24 April 2022]. （原始內容存檔於24 April 2022）.
- ^ Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform (新聞稿). Celltrion. 11 February 2021 [4 March 2021]. （原始內容存檔於19 October 2021） –透過Business Wire.
- ^ Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59 (新聞稿). Celltrion. 13 January 2021 [4 March 2021]. （原始內容存檔於19 October 2021） –透過Business Wire.
- ^ EMA issues advice on use of regdanvimab for treating COVID-19. European Medicines Agency. 26 March 2021 [15 October 2021]. （原始內容存檔於15 November 2021）.
延伸閱讀
編輯- Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nature Communications //www.ncbi.nlm.nih.gov/pmc/articles/PMC7803729
|PMC=缺少標題 (幫助). January 2021, 12 (1): 288. PMC 7803729
. PMID 33436577. doi:10.1038/s41467-020-20602-5 . - Syed YY. Regdanvimab: First Approval. Drugs //www.ncbi.nlm.nih.gov/pmc/articles/PMC8558754
|PMC=缺少標題 (幫助). December 2021, 81 (18): 2133–7. PMC 8558754 . PMID 34724174. doi:10.1007/s40265-021-01626-7 .
外部連結
編輯- Regdanvimab. Drug Information Portal. U.S. National Library of Medicine. [2023-12-19]. （原始內容存檔於2022-11-27）.